Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...
Dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine combined with amodiaquine reduced malaria incidence by 94% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback